Physician profile
Lawrence Curry
NPI 1104821313
$5,466.83
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $1,207 · 2021: $2,376 · 2022: $708 · 2023: $50.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $777.10 | 2019-2022 | |
| Abbvie INC. | $759.31 | 2021-2023 | Vraylar |
| Biohaven Pharmaceuticals, INC. | $467.10 | 2020-2021 | |
| Pfizer INC. | $395.41 | 2019-2022 | |
| Allergan, INC. | $346.27 | 2019-2020 | |
| Glaxosmithkline, LLC. | $342.30 | 2019-2021 | |
| Amgen INC. | $187.08 | 2019-2023 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $185.61 | 2019-2022 | |
| Insulet Corporation | $162.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $152.02 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.09 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.79 | 2019-2021 | |
| Esperion Therapeutics, INC. | $124.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $98.80 | 2019-2021 | |
| Lilly USA, LLC | $94.39 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.